Trial for this rare genetic disease to be conducted by NIH/NIAID in partnership with Corvus ITK inhibition intended to address…
CHARLESTOWN, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic…
Alzheimer’s disease (AD), affecting around 6.9 million people in the US, is ranked as the seventh leading cause of death…
Dr. Heidi Wang Accepts Award on Behalf of OBI Pharma at ADC Asia Congress 2025 and Gives a PresentationTAIPEI, Taiwan,…
Marks third FDA designation for ATSN-201, which has also received Rare Pediatric Disease Designation and Orphan Drug DesignationDURHAM, N.C., March…
NEW YORK, March 12, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory…
Denifanstat Phase 3 MASH program initiated in Q4 2024; patient screening expected to start in 1H 2025 Denifanstat received Breakthrough…
– Completed enrollment of Phase 2 clinical trial of verekitug in patients with chronic rhinosinusitis with nasal polyps; top-line data…
Management to host investor conference call today, March 12th, at 8:30am ETMIAMI, March 12, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc.…
Dr. Anatoly Dritschilo remains Chairman of the Board and Co-CEO overseeing scientific and clinical trial activitiesGAITHERSBURG, Md., March 12, 2025…